The drug major had posted a net profit of Rs 1,362 crore during the same period of previous fiscal.
Net sales of the company rose to Rs 4,751 crore for the second quarter, up 13 per cent, from the same period of previous fiscal, Sun Pharmaceutical Industries said in a filing to the BSE.
"Our Q2 performance was strong and continued to achieve high level of profitable growth, in-line with our expectations, " Sun Pharma Managing Director Dilip Shanghvi said.
In a separate filing, the company said its board has approved merger of Sun Pharma Global Inc, a wholly owned foreign subsidiary of the company, with itself, with effect from January 1, 2015.
Sun Pharma shares closed marginally up 0.26 per cent at Rs 908.60 apeice on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
